

Stephen J Clarke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/391072/publications.pdf>

Version: 2024-02-01

281
papers

19,764
citations

20036

63
h-index

14386

132
g-index

288
all docs

288
docs citations

288
times ranked

27348
citing authors

#	ARTICLE	IF	CITATIONS
1	Computed tomography (CT)-defined sarcopenia and myosteatosis are prevalent in patients with neuroendocrine neoplasms (NENs) treated with peptide receptor radionuclide therapy (PRRT). <i>European Journal of Clinical Nutrition</i> , 2022, 76, 143-149.	1.3	8
2	Clinical and molecular profile of young adults with early-onset colorectal cancer: Experience from four Australian tertiary centers. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, , .	0.7	1
3	Exploring the role of extracellular vesicles and their protein cargo in lung cancer metastasis: A review. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 171, 103603.	2.0	5
4	Liver Isolation Oxaliplatin (LIOX): Long Term Survival from a New Locoregional Technique for Chemorefractory Patients with Colorectal Liver Metastases. <i>Annals of Surgical Oncology</i> , 2022, 29, 3387-3389.	0.7	1
5	Effect of Cancer Pain Guideline Implementation on Pain Outcomes Among Adult Outpatients With Cancer-Related Pain. <i>JAMA Network Open</i> , 2022, 5, e220060.	2.8	6
6	Increased rates of cetuximab reactions in tick prevalent regions and a proposed protocol for risk mitigation. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 448-453.	0.7	8
7	Australian recommendations for the management of hepatocellular carcinoma: a consensus statement. <i>Medical Journal of Australia</i> , 2021, 214, 475-483.	0.8	36
8	Plasma pre-treatment T790M relative allelic frequency in patients with advanced EGFR-mutated non-small cell lung cancer predicts treatment response to subsequent-line osimertinib. <i>Translational Lung Cancer Research</i> , 2021, 10, 1623-1634.	1.3	5
9	Emerging biological therapies for the treatment of malignant pleural mesothelioma. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 179-192.	1.0	3
10	Safety and efficacy of the anti-CD73 monoclonal antibody (mAb) oleclumab ± durvalumab in patients (pts) with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or EGFR-mutant non-small cell lung cancer (EGFRm NSCLC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9047-9047.	0.8	28
11	EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, e859-e869.	1.1	23
12	Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors. <i>Lung Cancer</i> , 2021, 155, 28-33.	0.9	18
13	The Gut Microbiome and Gastrointestinal Toxicities in Pelvic Radiation Therapy: A Clinical Review. <i>Cancers</i> , 2021, 13, 2353.	1.7	15
14	Marked improvement in hyperammonaemic encephalopathy from multimodal treatment of metastatic neuroendocrine tumour. <i>BMJ Case Reports</i> , 2021, 14, e241191.	0.2	2
15	Optimal Upfront Treatment in Surgically Resectable Pancreatic Cancer Candidates: A High-Volume Center Retrospective Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2700.	1.0	5
16	The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?. <i>Cancers</i> , 2021, 13, 4824.	1.7	29
17	Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions. <i>Lung Cancer</i> , 2021, 159, 66-73.	0.9	17
18	Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review. <i>Frontiers in Oncology</i> , 2021, 11, 706331.	1.3	15

#	ARTICLE	IF	CITATIONS
19	Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2543-2550.	0.5	8
20	Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110196.	1.4	27
21	A Critical Assessment of Postneoadjuvant Therapy Pancreatic Cancer Regression Grading Schemes With a Proposal for a Novel Approach. <i>American Journal of Surgical Pathology</i> , 2021, 45, 394-404.	2.1	15
22	Life-threatening diarrhea in neuroendocrine tumors: two case reports. <i>Journal of Medical Case Reports</i> , 2021, 15, 542.	0.4	2
23	The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy. <i>Acta Oncol</i> , 2020, 59, 20-27.	0.8	3
24	High Metabolic Tumour Volume on 18-Fluorodeoxyglucose Positron Emission Tomography Predicts Poor Survival from Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2020, 110, 950-958.	1.2	19
25	Estimating survival in advanced cancer: a comparison of estimates made by oncologists and patients. <i>Supportive Care in Cancer</i> , 2020, 28, 3399-3407.	1.0	15
26	Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. <i>Annals of Oncology</i> , 2020, 31, 1553-1560.	0.6	76
27	The Effects of Acupuncture on Cancer-Related Fatigue: Updated Systematic Review and Meta-Analysis. <i>Integrative Cancer Therapies</i> , 2020, 19, 153473542094967.	0.8	30
28	Science and art of anticancer drug dosing: nine steps to personalised therapy. <i>Internal Medicine Journal</i> , 2020, 50, 992-996.	0.5	0
29	Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay. <i>Nanotheranostics</i> , 2020, 4, 224-232.	2.7	25
30	Red blood cells exposed to cancer cells in culture have altered cytokine profiles and immune function. <i>Scientific Reports</i> , 2020, 10, 7727.	1.6	12
31	ALK-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling. <i>Oncologist</i> , 2020, 25, 641-649.	1.9	8
32	Cyto-Immuno-Therapy for Cancer: A Pathway Elicited by Tumor-Targeted, Cytotoxic Drug-Packaged Bacterially Derived Nanocells. <i>Cancer Cell</i> , 2020, 37, 354-370.e7.	7.7	34
33	Identification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant Chemotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 237.	1.3	22
34	The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT]. <i>PLoS ONE</i> , 2020, 15, e0229900.	1.1	12
35	Evaluation of Fluorodeoxyglucose Positron Emission Tomography Scanning in the Neoadjuvant Therapy Paradigm in Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2020, 49, 224-229.	0.5	9
36	Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma model. <i>PLoS ONE</i> , 2020, 15, e0226444.	1.1	16

#	ARTICLE	IF	CITATIONS
37	The Effects of Tai Chi and Qigong on Immune Responses: A Systematic Review and Meta-Analysis. <i>Medicines (Basel, Switzerland)</i> , 2020, 7, 39.	0.7	19
38	Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical Outcomes. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1013-1026.	1.6	3
39	A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 142, 34-40.	0.9	27
40	Extracellular vesicles as biomarkers in malignant pleural mesothelioma: A review. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 150, 102949.	2.0	20
41	Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100075.	0.6	8
42	Serum bicarbonate is a marker of peri-operative mortality but is not associated with long term survival in colorectal cancer. <i>PLoS ONE</i> , 2020, 15, e0228466.	1.1	4
43	Altered cytochrome 2E1 and 3A P450-dependent drug metabolism in advanced ovarian cancer correlates to tumour-associated inflammation. <i>British Journal of Pharmacology</i> , 2019, 176, 3712-3722.	2.7	14
44	Mass Cytometry Reveals a Sustained Reduction in CD16+ Natural Killer Cells Following Chemotherapy in Colorectal Cancer Patients. <i>Frontiers in Immunology</i> , 2019, 10, 2584.	2.2	9
45	Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2019, 63, 272-280.	0.9	6
46	Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study. <i>European Journal of Cancer</i> , 2019, 109, 28-35.	1.3	69
47	Treatment and management of adrenal cancer in a specialized Australian endocrine surgical unit: approaches, outcomes and lessons learnt. <i>ANZ Journal of Surgery</i> , 2019, 89, 48-52.	0.3	4
48	Straddling medical specialties: should we have more comprehensive advanced training?. <i>Internal Medicine Journal</i> , 2019, 49, 669-671.	0.5	1
49	Tumor sidedness is not an independent prognostic marker of colorectal cancer patients undergoing curative resection: A retrospective cohort study. <i>PLoS ONE</i> , 2019, 14, e0218207.	1.1	6
50	Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2019, 111, 782-794.	3.0	223
51	Mouse Model of Mutated in Colorectal Cancer Gene Deletion Reveals Novel Pathways in Inflammation and Cancer. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019, 7, 819-839.	2.3	11
52	High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes. <i>Lung Cancer</i> , 2019, 130, 35-41.	0.9	17
53	The vermiform appendix: an immunological organ sustaining a microbiome inoculum. <i>Clinical Science</i> , 2019, 133, 1-8.	1.8	46
54	Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study. <i>European Journal of Surgical Oncology</i> , 2019, 45, 218-224.	0.5	22

#	ARTICLE	IF	CITATIONS
55	A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. <i>Journal of the National Cancer Institute</i> , 2019, 111, 575-583.	3.0	96
56	Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1504.	1.3	4
57	Challenges in chemotherapy delivery: comparison of standard chemotherapy delivery to locoregional vascular mass fluid transfer. <i>Future Oncology</i> , 2018, 14, 647-663.	1.1	23
58	Pattern of care and survival of anaplastic lymphoma kinase rearranged non-“small cell lung cancer (<i>ALK</i>+ NSCLC) in an Australian Metropolitan Tertiary Referral Centre: A retrospective cohort analysis. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e275-e282.	0.7	6
59	Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. <i>Journal of the National Cancer Institute</i> , 2018, 110, 638-648.	3.0	90
60	Neutrophil to lymphocyte ratio and early clinical outcomes in patients with acute ischemic stroke. <i>Journal of the Neurological Sciences</i> , 2018, 387, 115-118.	0.3	72
61	Prognostic indices of inflammatory markers, cognitive function and fatigue for survival in patients with localised colorectal cancer. <i>ESMO Open</i> , 2018, 3, e000302.	2.0	8
62	A Longitudinal Investigation of Inflammatory Markers in Colorectal Cancer Patients Perioperatively Demonstrates Benefit in Serial Remeasurement. <i>Annals of Surgery</i> , 2018, 267, 1119-1125.	2.1	33
63	Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. <i>Gut</i> , 2018, 67, 2142-2155.	6.1	100
64	Complete response in a patient with stage IV adrenocortical carcinoma treated with adjuvant transcatheter arterial chemoembolization (TACE). <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 279-281.	0.7	9
65	Patient-reported experience of the impact and burden of neuroendocrine tumors: Oceania patient results from a large global survey. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 256-263.	0.7	8
66	Acupuncture in Oncology: The Effectiveness of Acupuncture May Not Depend on Needle Retention Duration. <i>Integrative Cancer Therapies</i> , 2018, 17, 458-466.	0.8	9
67	Ado-Trastuzumab Emtansine for Patients With <i>HER2</i>-Mutant Lung Cancers: Results From a Phase II Basket Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2532-2537.	0.8	381
68	Do EGFR tyrosine kinase inhibitors (TKIs) still have a role in EGFR wild-type pre-treated advanced non-small cell lung cancer (NSCLC)?“the shifting paradigm of therapeutics. <i>Translational Lung Cancer Research</i> , 2018, 7, S39-S45.	1.3	11
69	The role of adjuvant probiotics to attenuate intestinal inflammatory responses due to cancer treatments. <i>Beneficial Microbes</i> , 2018, 9, 899-916.	1.0	14
70	A randomised controlled trial of an advance care planning intervention for patients with incurable cancer. <i>British Journal of Cancer</i> , 2018, 119, 1182-1190.	2.9	54
71	The integration of pharmacology and pathophysiology into locoregional chemotherapy delivery via mass fluid transfer. <i>Journal of Controlled Release</i> , 2018, 292, 18-28.	4.8	2
72	Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV). <i>BMJ Open</i> , 2018, 8, e020745.	0.8	16

#	ARTICLE	IF	CITATIONS
73	The role of proteomics in the age of immunotherapies. <i>Mammalian Genome</i> , 2018, 29, 757-769.	1.0	12
74	Accreditation Standard Guideline Initiative for Tai Chi and Qigong Instructors and Training Institutions. <i>Medicines (Basel, Switzerland)</i> , 2018, 5, 51.	0.7	6
75	A data-driven, knowledge-based approach to biomarker discovery: application to circulating microRNA markers of colorectal cancer prognosis. <i>Npj Systems Biology and Applications</i> , 2018, 4, 20.	1.4	47
76	Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. <i>Clinical Colorectal Cancer</i> , 2018, 17, e617-e629.	1.0	54
77	Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4123-4123.	0.8	64
78	The Lymphocyte-to-Monocyte Ratio is a Superior Predictor of Overall Survival in Comparison to Established Biomarkers of Resectable Colorectal Cancer. <i>Annals of Surgery</i> , 2017, 265, 539-546.	2.1	225
79	Systematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2017, 104, 209-222.	1.2	13
80	Factors Affecting Whether Or Not Cancer Patients Consider Using Acupuncture. <i>Acupuncture in Medicine</i> , 2017, 35, 107-113.	0.4	10
81	Impact of physical activity on fatigue and quality of life in people with advanced lung cancer: a randomized controlled trial. <i>Annals of Oncology</i> , 2017, 28, 1889-1897.	0.6	81
82	Clinical and imaging-based prognostic factors in radioembolisation of liver metastases from colorectal cancer: a retrospective exploratory analysis. <i>EJNMMI Research</i> , 2017, 7, 46.	1.1	45
83	Prognostic and predictive biomarkers in neuroendocrine tumours. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 268-282.	2.0	42
84	Osimertinib induced bullous dermatitis. <i>Cancer Treatment and Research Communications</i> , 2017, 13, 25-26.	0.7	1
85	Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. <i>Lancet Oncology, The</i> , 2017, 18, 1386-1396.	5.1	508
86	Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 296-303.	0.7	15
87	Cancer-Related Systemic Inflammation: The Challenges and Therapeutic Opportunities for Personalized Medicine. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 599-610.	2.3	68
88	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. <i>Lancet Oncology, The</i> , 2017, 18, 1159-1171.	5.1	293
89	Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre. <i>European Journal of Surgical Oncology</i> , 2017, 43, 1711-1717.	0.5	28
90	Screening for ROS1 gene rearrangements in non-small cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target. <i>Histopathology</i> , 2017, 70, 402-411.	1.6	52

#	ARTICLE	IF	CITATIONS
91	Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial. <i>International Journal of Cancer</i> , 2017, 140, 431-439.	2.3	4
92	Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance. <i>Theranostics</i> , 2017, 7, 1149-1158.	4.6	201
93	Changing Therapeutic Paradigms: Predicting mCRC Lesion Response to Selective Internal Radionuclide Therapy (SIRT) based on Critical Absorbed Dose Thresholds: A Case Study. <i>Asia Oceania Journal of Nuclear Medicine and Biology</i> , 2017, 5, 66-69.	0.1	2
94	PET monitoring of liver directed selective internal radionuclide therapy for metastatic gastro-oesophageal cancer. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016215645.	0.2	0
95	Primary Pericardial Sarcoma with Right Atrial Invasion and Multiple Bilateral Pulmonary Metastases in a Patient with Hereditary Nonpolyposis Colorectal Cancer. <i>Case Reports in Oncological Medicine</i> , 2016, 2016, 1-4.	0.2	0
96	Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET). <i>PLoS ONE</i> , 2016, 11, e0158140.	1.1	22
97	Oxidative stress in prostate cancer patients: A systematic review of case control studies. <i>Prostate International</i> , 2016, 4, 71-87.	1.2	63
98	Analytical performance of nanoLC-MS/MS using nondepleted human plasma over an 18-month period. <i>Proteomics</i> , 2016, 16, 2118-2127.	1.3	6
99	Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. <i>Epigenomics</i> , 2016, 8, 1079-1085.	1.0	176
100	Inflammatory Markers Have a Role in Renal Cell Carcinoma Prognosis. <i>European Urology Focus</i> , 2016, 2, 341-342.	1.6	6
101	Eastern Cooperative Oncology Group score: Agreement between non-small-cell lung cancer patients and their oncologists and clinical implications. <i>Cancer Treatment Communications</i> , 2016, 5, 17-21.	0.4	15
102	Fatigue in people with localized colorectal cancer who do and do not receive chemotherapy: a longitudinal prospective study. <i>Annals of Oncology</i> , 2016, 27, 1761-1767.	0.6	52
103	Exhaled breath condensate for lung cancer protein analysis: a review of methods and biomarkers. <i>Journal of Breath Research</i> , 2016, 10, 034001.	1.5	33
104	The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. <i>Lung Cancer</i> , 2016, 102, 21-27.	0.9	11
105	Advance care planning in patients with incurable cancer: study protocol for a randomised controlled trial. <i>BMJ Open</i> , 2016, 6, e012387.	0.8	21
106	Safety and Feasibility of Repeatable Hepatic Vascular Isolation Chemotherapy: A Pilot Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 3699-3708.	0.7	4
107	Systemic inflammation is an independent predictive marker of clinical outcomes in mucosal squamous cell carcinoma of the head and neck in oropharyngeal and non-oropharyngeal patients. <i>BMC Cancer</i> , 2016, 16, 124.	1.1	57
108	A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma. <i>British Journal of Cancer</i> , 2016, 114, 524-531.	2.9	20

#	ARTICLE	IF	CITATIONS
109	Symptom Clusters in Advanced Cancer Patients: An Empirical Comparison of Statistical Methods and the Impact on Quality of Life. <i>Journal of Pain and Symptom Management</i> , 2016, 51, 88-98.	0.6	68
110	The lymphocyte-to-monocyte ratio as a predictor of overall survival in comparison to established systemic markers of inflammation in resectable colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 593-593.	0.8	1
111	Adjuvant therapy in pancreatic adenocarcinoma: A systemic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 330-330.	0.8	0
112	Change in inflammatory status as a prognostic marker of overall survival in colorectal patients undergoing resection.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6571-6571.	0.8	0
113	Neutrophil-to-lymphocyte ratio in head and neck cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2015, 59, 514-519.	0.9	46
114	Somatostatin Receptor SSTR-2a Expression Is a Stronger Predictor for Survival Than Ki-67 in Pancreatic Neuroendocrine Tumors. <i>Medicine (United States)</i> , 2015, 94, e1281.	0.4	56
115	Adjuvant Iodine ¹³¹ Lipiodol after Resection of Hepatocellular Carcinoma. <i>Journal of Oncology</i> , 2015, 2015, 1-7.	0.6	7
116	microRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma. <i>Oncotarget</i> , 2015, 6, 36675-36688.	0.8	79
117	Malignant Cardiac Tamponade from Non-Small Cell Lung Cancer: Case Series from the Era of Molecular Targeted Therapy. <i>Journal of Clinical Medicine</i> , 2015, 4, 75-84.	1.0	14
118	Pathogenic PALB2 mutation in metastatic pancreatic adenocarcinoma and neuroendocrine tumour: A case report. <i>Molecular and Clinical Oncology</i> , 2015, 3, 817-819.	0.4	10
119	Surface profiles of live colorectal cancer cells and tumor infiltrating lymphocytes from surgical samples correspond to prognostic categories. <i>Journal of Immunological Methods</i> , 2015, 416, 59-68.	0.6	8
120	Improving Outcomes in Adrenocortical Cancer: An Australian Perspective. <i>Annals of Surgical Oncology</i> , 2015, 22, 2309-2316.	0.7	20
121	The relationship between nutritional status, inflammatory markers and survival in patients with advanced cancer: a prospective cohort study. <i>Supportive Care in Cancer</i> , 2015, 23, 385-391.	1.0	79
122	Dramatic response to selective internal radiation therapy for unresectable hepatocellular carcinoma. <i>Oxford Medical Case Reports</i> , 2015, 2015, 194-195.	0.2	0
123	Localized malignant pleural mesothelioma with renal metastasis. <i>Oxford Medical Case Reports</i> , 2015, 2015, 170-172.	0.2	11
124	A Significant Metabolic and Radiological Response after a Novel Targeted MicroRNA-based Treatment Approach in Malignant Pleural Mesothelioma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 1467-1469.	2.5	66
125	Reporting in studies of protein biomarkers of prognosis in colorectal cancer in relation to the REMARK guidelines. <i>Proteomics - Clinical Applications</i> , 2015, 9, 1078-1086.	0.8	7
126	Immunohistochemical Validation of Overexpressed Genes Identified by Global Expression Microarrays in Adrenocortical Carcinoma Reveals Potential Predictive and Prognostic Biomarkers. <i>Oncologist</i> , 2015, 20, 247-256.	1.9	19

#	ARTICLE	IF	CITATIONS
127	Cognitive Function in Patients With Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 4085-4092.	0.8	168
128	Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: An evidence-based benchmark for cancer care. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2015, 11, 85-92.	0.7	4
129	Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2015, 11, 4-14.	0.7	15
130	Preliminary direct evidence of a dose-response relationship for [Y-90]-microsphere selective internal radionuclide therapy (SIRT) in hepatic malignancy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 11064-11064.	0.8	1
131	The impact of physical activity on fatigue and quality of life in lung cancer patients: A randomised controlled trial (RCT).. <i>Journal of Clinical Oncology</i> , 2015, 33, 9507-9507.	0.8	2
132	Biomarkers in Metastatic Colorectal Cancer. <i>Biomarkers in Disease</i> , 2015, , 601-629.	0.0	1
133	Nomograms for overall survival (OS) and progression-free survival (PFS) in metastatic colorectal cancer (mCRC): Construction from 19,678 ARCAD patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 659-659.	0.8	0
134	Neutrophil/lymphocyte ratio (NLR) and FDG PET as predictive measures of response and prognosis in patients treated with Y-90 microsphere selective internal radionuclide therapy (SIRT).. <i>Journal of Clinical Oncology</i> , 2015, 33, e22137-e22137.	0.8	0
135	Calculators for overall survival (OS) and progression-free survival (PFS) in metastatic colorectal cancer (mCRC): Construction from 19,678 ARCAD patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3555-3555.	0.8	0
136	Diagnosis of gastrointestinal bleeding: A practical guide for clinicians. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2014, 5, 467.	0.5	151
137	Streptavidin: A Novel Immunostimulant for the Selection and Delivery of Autologous and Syngeneic Tumor Vaccines. <i>Cancer Immunology Research</i> , 2014, 2, 469-479.	1.6	22
138	Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study. <i>BMC Cancer</i> , 2014, 14, 897.	1.1	54
139	Comment on "Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma". <i>British Journal of Cancer</i> , 2014, 111, 2376-2376.	2.9	3
140	Cognitive function and fatigue after diagnosis of colorectal cancer. <i>Annals of Oncology</i> , 2014, 25, 2404-2412.	0.6	101
141	Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. <i>British Journal of Cancer</i> , 2014, 111, 1860-1869.	2.9	68
142	Enduring complete metabolic response in metastatic adenocarcinoma of the gastro-oesophageal junction. <i>Oxford Medical Case Reports</i> , 2014, 2014, 105-106.	0.2	0
143	From mice to men: GEMMs as trial patients for new NSCLC therapies. <i>Seminars in Cell and Developmental Biology</i> , 2014, 27, 118-127.	2.3	19
144	Adverse Tumor Biology Associated with Mesenterico-Portal Vein Resection Influences Survival in Patients with Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 1937-1947.	0.7	36

#	ARTICLE	IF	CITATIONS
145	Comprehensive glycomics comparison between colon cancer cell cultures and tumours: Implications for biomarker studies. <i>Journal of Proteomics</i> , 2014, 108, 146-162.	1.2	57
146	<i>KRAS</i> mutations and <i>CDKN2A</i> promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer. <i>International Journal of Cancer</i> , 2014, 134, 2820-2828.	2.3	44
147	Cancer-related inflammation and treatment effectiveness. <i>Lancet Oncology</i> , The, 2014, 15, e493-e503.	5.1	1,525
148	Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 317-324.	0.9	60
149	Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma. <i>Scientific Reports</i> , 2014, 4, 6152.	1.6	20
150	Effects of qigong on quality of life, fatigue, stress, neuropathy, and sexual function in women with metastatic breast cancer: A feasibility study.. <i>Journal of Clinical Oncology</i> , 2014, 32, e20712-e20712.	0.8	2
151	Depletion of White Adipose Tissue in Cancer Cachexia Syndrome Is Associated with Inflammatory Signaling and Disrupted Circadian Regulation. <i>PLoS ONE</i> , 2014, 9, e92966.	1.1	69
152	Prognostic significance of circulating secreted protein acidic and rich in cysteine (SPARC) in malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2014, 32, 7580-7580.	0.8	0
153	Old and new prognostic factors in a series of 910 patients with malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2014, 32, 7586-7586.	0.8	0
154	Prognostic utility of the preoperative neutrophil/lymphocyte ratio combined with BRAF and MMR status in colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, e14529-e14529.	0.8	0
155	Extra-Hepatic Cancer Represses Hepatic Drug Metabolism Via Interleukin (IL)-6 Signalling. <i>Pharmaceutical Research</i> , 2013, 30, 2270-2278.	1.7	14
156	An Australian translational Study to evaluate the prognostic role of inflammatory markers in patients with metastatic Colorectal cancer Treated with bevacizumab (Avastin,®) [ASCENT]. <i>BMC Cancer</i> , 2013, 13, 120.	1.1	18
157	Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma. <i>Supportive Care in Cancer</i> , 2013, 21, 1879-1884.	1.0	8
158	<i>CYP3A4</i> intron 6 C&T SNP (<i>CYP3A4*22</i>) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. <i>Pharmacogenomics</i> , 2013, 14, 137-149.	0.6	51
159	Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer. <i>SpringerPlus</i> , 2013, 2, 126.	1.2	18
160	The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 218-230.	2.0	1,106
161	Overview of biomarkers in metastatic colorectal cancer: Tumour, blood and patient-related factors. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 121-135.	2.0	19
162	Glasgow Prognostic Score As a Prognostic Factor in Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel-Based Chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 423-430.	0.9	36

#	ARTICLE	IF	CITATIONS
163	Preoperative neutrophil/lymphocyte ratio predicts overall survival but does not predict recurrence or cancer-specific survival after curative resection of node-positive colorectal cancer. <i>BMC Cancer</i> , 2013, 13, 442.	1.1	38
164	A randomized controlled pilot trial comparing the impact of access to clinical endocrinology video demonstrations with access to usual revision resources on medical student performance of clinical endocrinology skills. <i>BMC Medical Education</i> , 2013, 13, 135.	1.0	37
165	Patterns of care for malignant pleural mesothelioma patients compensated by the <sc>D</sc>ust <sc>D</sc>iseases <sc>B</sc>oard in <sc>N</sc>ew <sc>S</sc>outh <sc>W</sc>ales, <sc>A</sc>ustralia. <i>Internal Medicine Journal</i> , 2013, 43, 402-410.	0.5	16
166	Health-related quality of life and inflammatory markers in malignant pleural mesothelioma. <i>Supportive Care in Cancer</i> , 2013, 21, 697-705.	1.0	38
167	Vitamin supplementation in patients receiving pemetrexed for advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2013, 82, 511.	0.9	1
168	Excision Repair Cross Complementation Group 1 and Thymidylate Synthase Expression in Patients With Mesothelioma. <i>Clinical Lung Cancer</i> , 2013, 14, 164-171.	1.1	8
169	Validation of Prognostic Factors in Malignant Pleural Mesothelioma: A Retrospective Analysis of Data from Patients Seeking Compensation from the New South Wales Dust Diseases Board. <i>Clinical Lung Cancer</i> , 2013, 14, 70-77.	1.1	50
170	BRAFV600E Immunohistochemistry Facilitates Universal Screening of Colorectal Cancers for Lynch Syndrome. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1592-1602.	2.1	125
171	Randomized Controlled Trial of a Structured Intervention to Facilitate End-of-Life Decision Making in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3403-3410.	0.8	81
172	Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: Trends in Australia and a literature review. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2013, 9, 273-279.	0.7	9
173	Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 148-155.	0.7	35
174	Diagnostic Accuracy of Imaging Modalities in the Evaluation of Vascular Invasion in Pancreatic Adenocarcinoma: A Meta-Analysis. <i>World Journal of Oncology</i> , 2013, 4, 74-82.	0.6	8
175	Use of inflammatory markers to triage cancer patients requiring nutritional assessment and interventions.. <i>Journal of Clinical Oncology</i> , 2013, 31, e17541-e17541.	0.8	0
176	A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. <i>British Journal of Cancer</i> , 2012, 107, 695-699.	2.9	391
177	Src tyrosine kinase phosphorylation of nuclear receptor HNF4 β correlates with isoform-specific loss of HNF4 β in human colon cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2302-2307.	3.3	76
178	The eligibility of advanced non-small-cell lung cancer patients for targeted therapy clinical trials. <i>Annals of Oncology</i> , 2012, 23, 1229-1233.	0.6	17
179	Activation of Thermogenesis in Brown Adipose Tissue and Dysregulated Lipid Metabolism Associated with Cancer Cachexia in Mice. <i>Cancer Research</i> , 2012, 72, 4372-4382.	0.4	133
180	A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer. <i>Oncology Reports</i> , 2012, 28, 763-767.	1.2	3

#	ARTICLE	IF	CITATIONS
181	Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. <i>Lancet Oncology</i> , The, 2012, 13, 1225-1233.	5.1	484
182	The ticking time-bomb of asbestos: Its insidious role in the development of malignant mesothelioma. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, 200-212.	2.0	51
183	Remarkable temporal stability of high-abundance human plasma proteins assessed by targeted mass spectrometry. <i>Proteomics - Clinical Applications</i> , 2012, 6, 626-634.	0.8	6
184	Body image as a predictor of psychopathology in surgical patients with colorectal disease. <i>Journal of Psychosomatic Research</i> , 2012, 73, 459-463.	1.2	55
185	Overexpression of protein S100A4 is independently associated with overall survival in stage C colonic cancer but only in cytoplasm at the advancing tumour front. <i>International Journal of Colorectal Disease</i> , 2012, 27, 1409-1417.	1.0	7
186	Cancer Patient Disclosure and Patient-Doctor Communication of Complementary and Alternative Medicine Use: A Systematic Review. <i>Oncologist</i> , 2012, 17, 1475-1481.	1.9	265
187	Corrigendum to "Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis" [Eur J Cancer 47 (12) (2011) 1826-1836]. <i>European Journal of Cancer</i> , 2012, 48, 407.	1.3	0
188	Glutathione S-transferase Pi expression predicts response to adjuvant chemotherapy for stage C colon cancer: a matched historical control study. <i>BMC Cancer</i> , 2012, 12, 196.	1.1	11
189	The impact of physical activity on fatigue and quality of life in lung cancer patients: a randomised controlled trial protocol. <i>BMC Cancer</i> , 2012, 12, 572.	1.1	31
190	Pharmacokinetics and Pharmacodynamics of Intraperitoneal Cancer Chemotherapeutics. <i>Clinical Pharmacokinetics</i> , 2012, 51, 203-224.	1.6	72
191	The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. <i>Lung Cancer</i> , 2012, 75, 248-254.	0.9	30
192	A Critical Review of the Effects of Medical Qigong on Quality of Life, Immune Function, and Survival in Cancer Patients. <i>Integrative Cancer Therapies</i> , 2012, 11, 101-110.	0.8	52
193	Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a randomized controlled trial. <i>Supportive Care in Cancer</i> , 2012, 20, 1235-1242.	1.0	179
194	Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer. <i>Supportive Care in Cancer</i> , 2012, 20, 1869-1874.	1.0	32
195	Use of adjuvant chemotherapy in stage C (III) rectal cancer: Comparison of data from matched patients in a teaching hospital's clinicopathological database. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2012, 8, 346-355.	0.7	1
196	Reporting clinical trial information: colorectal cancer trials at Sydney Cancer Centre. <i>Internal Medicine Journal</i> , 2012, 42, 416-421.	0.5	0
197	Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C14-erythromycin breath test and the antipyrine clearance test. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 125-135.	1.1	18
198	Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4644-4644.	0.8	1

#	ARTICLE	IF	CITATIONS
199	Cognitive function and fatigue in colorectal cancer (CRC) patients: A prospective longitudinal controlled study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9021-9021.	0.8	2
200	Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting. <i>Aging</i> , 2012, 4, 133-143.	1.4	72
201	Inflammation in malignant mesothelioma - friend or foe?. <i>Annals of Cardiothoracic Surgery</i> , 2012, 1, 516-22.	0.6	24
202	Pathophysiology of Bone Metastases. , 2012, , 59-84.		0
203	XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. <i>British Journal of Cancer</i> , 2011, 105, 58-64.	2.9	184
204	Use of Inflammatory Markers to Guide Cancer Treatment. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 475-478.	2.3	73
205	Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis. <i>European Journal of Cancer</i> , 2011, 47, 1826-1836.	1.3	17
206	The relationship between body image disturbance and distress in colorectal cancer patients with and without stomas. <i>Journal of Psychosomatic Research</i> , 2011, 70, 395-402.	1.2	101
207	Accuracy of Diagnostic Biopsy for the Histological Subtype of Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2011, 6, 602-605.	0.5	53
208	Validation of tissue microarray technology in malignant pleural mesothelioma. <i>Pathology</i> , 2011, 43, 128-132.	0.3	26
209	Low Calretinin Expression and High Neutrophil-To-Lymphocyte Ratio Are Poor Prognostic Factors in Patients with Malignant Mesothelioma Undergoing Extrapleural Pneumonectomy. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1923-1929.	0.5	82
210	Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing. <i>Journal of Visualized Experiments</i> , 2011, , .	0.2	10
211	Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma. <i>Pathology</i> , 2011, 43, 313-317.	0.3	17
212	Clinicopathological correlates and prognostic significance of glutathione S-transferase Pi expression in 468 patients after potentially curative resection of node-positive colonic cancer. <i>Histopathology</i> , 2011, 59, 1057-1070.	1.6	12
213	Randomized phase 2 sequencing and pharmacokinetic study of gemcitabine and oxaliplatin in advanced non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011, 7, 376-384.	0.7	1
214	Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. <i>British Journal of Cancer</i> , 2011, 104, 1288-1295.	2.9	402
215	Using the distress thermometer and hospital anxiety and depression scale to screen for psychosocial morbidity in patients diagnosed with colorectal cancer. <i>Journal of Affective Disorders</i> , 2011, 131, 412-416.	2.0	40
216	Proteomic comparison of colorectal tumours and non-neoplastic mucosa from paired patient samples using iTRAQ mass spectrometry. <i>Molecular BioSystems</i> , 2011, 7, 2997.	2.9	31

#	ARTICLE	IF	CITATIONS
217	Patient and oncologist estimates of survival in advanced cancer patients. <i>Psycho-Oncology</i> , 2011, 20, 213-218.	1.0	22
218	Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 79, 224-250.	2.0	38
219	Supporting Treatment Decision Making in Advanced Cancer: A Randomized Trial of a Decision Aid for Patients With Advanced Colorectal Cancer Considering Chemotherapy. <i>Journal of Clinical Oncology</i> , 2011, 29, 2077-2084.	0.8	95
220	Liver Membrane Proteome Glycosylation Changes in Mice Bearing an Extra-hepatic Tumor. <i>Molecular and Cellular Proteomics</i> , 2011, 10, M900538-MCP200.	2.5	38
221	Extrahepatic Cancer Suppresses Nuclear Receptor-Regulated Drug Metabolism. <i>Clinical Cancer Research</i> , 2011, 17, 3170-3180.	3.2	31
222	An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1395-1410.	1.5	19
223	Pharmacometabonomic Profiling as a Predictor of Toxicity in Patients with Inoperable Colorectal Cancer Treated with Capecitabine. <i>Clinical Cancer Research</i> , 2011, 17, 3019-3028.	3.2	102
224	Clinical Pharmacology of Chemotherapy Agents in Older People with Cancer. <i>Current Gerontology and Geriatrics Research</i> , 2011, 2011, 1-6.	1.6	11
225	Interaction Between Complementary and Alternative Medicines and Conventional Medicines. , 2011, , 227-259.		0
226	Predictive Markers for Haematological Toxicity of Pemetrexed. <i>Current Drug Targets</i> , 2010, 11, 48-57.	1.0	9
227	Is it prime time for personalized medicine in cancer treatment?. <i>Personalized Medicine</i> , 2010, 7, 387-397.	0.8	1
228	Surface antigen profiling of colorectal cancer using antibody microarrays with fluorescence multiplexing. <i>Journal of Immunological Methods</i> , 2010, 355, 40-51.	0.6	30
229	Identification of distinctive protein expression patterns in colorectal adenoma. <i>Proteomics - Clinical Applications</i> , 2010, 4, 60-70.	0.8	36
230	The use and perceived benefits resulting from the use of complementary and alternative medicine by cancer patients in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2010, 6, 342-349.	0.7	63
231	Clinicopathological correlates and prognostic significance of maspin expression in 450 patients after potentially curative resection of node-positive colonic cancer. <i>Histopathology</i> , 2010, 56, 319-330.	1.6	19
232	Inflammation and Cancer: Causes and Consequences. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 87, 504-508.	2.3	202
233	Malignant mesothelioma. <i>Internal Medicine Journal</i> , 2010, 40, 742-750.	0.5	31
234	Fascin Expression Predicts Survival After Potentially Curative Resection of Node-positive Colon Cancer. <i>American Journal of Surgical Pathology</i> , 2010, 34, 656-666.	2.1	34

#	ARTICLE	IF	CITATIONS
235	High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy. <i>Clinical Cancer Research</i> , 2010, 16, 5805-5813.	3.2	279
236	Clinical Trial Information As a Measure of Quality Cancer Care. <i>Journal of Oncology Practice</i> , 2010, 6, 170-171.	2.5	5
237	Impact of Medical Qigong on quality of life, fatigue, mood and inflammation in cancer patients: a randomized controlled trial. <i>Annals of Oncology</i> , 2010, 21, 608-614.	0.6	176
238	The alternatively spliced murine pregnane X receptor isoform, mPXR β 171-211 exhibits a repressive action. <i>International Journal of Biochemistry and Cell Biology</i> , 2010, 42, 672-682.	1.2	11
239	Adjuvant chemotherapy for early colon cancer: What survival benefits make it worthwhile?. <i>European Journal of Cancer</i> , 2010, 46, 1800-1807.	1.3	37
240	Patient-doctor communication: use of complementary and alternative medicine by adult patients with cancer. <i>Society for Integrative Oncology</i> , 2010, 8, 56-64.	0.8	25
241	Phase IV Study of Bevacizumab in Combination with Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in First-Line Metastatic Colorectal Cancer. <i>Oncology</i> , 2009, 77, 113-119.	0.9	106
242	Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials. <i>BMC Cancer</i> , 2009, 9, 130.	1.1	38
243	Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients – analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO. <i>BMC Cancer</i> , 2009, 9, 153.	1.1	25
244	Adjuvant chemotherapy for stage C colonic cancer in a multidisciplinary setting. <i>ANZ Journal of Surgery</i> , 2009, 79, 685-692.	0.3	5
245	Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2009, 101, 998-1004.	2.9	84
246	Cetuximab-Associated Pulmonary Toxicity. <i>Clinical Colorectal Cancer</i> , 2009, 8, 118-120.	1.0	38
247	Ethnic differences in drug metabolism and toxicity from chemotherapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 243-257.	1.5	106
248	Beyond Conventional Cancer Treatments: "The Use of Complementary Therapies During Cancer Treatment: Implications for Clinicians". , 2009, , 285-315.		2
249	Retrospective review of mitomycin C use as third-line chemotherapy in metastatic colorectal cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2008, 4, 132-136.	0.7	3
250	Systemic Inflammatory Response Predicts Prognosis in Patients with Advanced-Stage Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2008, 7, 331-337.	1.0	90
251	Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 137-149.	1.5	80
252	Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 2013-2019.	0.8	2,735

#	ARTICLE	IF	CITATIONS
253	Thymidylate Synthase and Methylenetetrahydrofolate Reductase Gene Polymorphisms and Toxicity to Capecitabine in Advanced Colorectal Cancer Patients. <i>Clinical Cancer Research</i> , 2008, 14, 817-825.	3.2	90
254	Medical Qigong for Cancer Patients: Pilot Study of Impact on Quality of Life, Side Effects of Treatment and Inflammation. <i>The American Journal of Chinese Medicine</i> , 2008, 36, 459-472.	1.5	68
255	Patient and Physician Preferences for Surgical and Adjuvant Treatment Options for Rectal Cancer. <i>Archives of Surgery</i> , 2008, 143, 389.	2.3	84
256	Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 2006-2012.	0.8	767
257	Modification of Leucovorin Dose Within a Simplified FOLFOX Regimen Improves Tolerability Without Compromising Efficacy. <i>Clinical Colorectal Cancer</i> , 2007, 6, 578-582.	1.0	3
258	The development of multiple reaction monitoring assays for liver-derived plasma proteins. <i>Proteomics - Clinical Applications</i> , 2007, 1, 1570-1581.	0.8	39
259	Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial. <i>Supportive Care in Cancer</i> , 2007, 15, 301-307.	1.0	115
260	Evaluation of Nutritional and Inflammatory Status of Advanced Colorectal Cancer Patients and Its Correlation With Survival. <i>Nutrition and Cancer</i> , 2006, 55, 78-85.	0.9	129
261	Predicting the Toxicity of Weekly Docetaxel in Advanced Cancer. <i>Clinical Pharmacokinetics</i> , 2006, 45, 611-622.	1.6	32
262	Prognostic Factors Predictive of Response and Survival to a Modified FOLFOX Regimen: Importance of an Increased Neutrophil Count. <i>Clinical Colorectal Cancer</i> , 2006, 6, 297-304.	1.0	29
263	ADVANCES IN THE ADJUVANT TREATMENT OF COLORECTAL CANCER. <i>ANZ Journal of Surgery</i> , 2006, 76, 373-380.	0.3	14
264	An evaluation of the prevalence of malnutrition in cancer patients attending the outpatient oncology clinic. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2006, 2, 80-86.	0.7	24
265	Relationship of Hepatic Functional Imaging to Irinotecan Pharmacokinetics and Genetic Parameters of Drug Elimination. <i>Journal of Clinical Oncology</i> , 2006, 24, 4228-4235.	0.8	31
266	Transcriptional Repression of Hepatic Cytochrome P450 3A4 Gene in the Presence of Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 7492-7497.	3.2	76
267	The relationship between available support, unmet needs and caregiver burden in patients with advanced cancer and their carers. <i>Psycho-Oncology</i> , 2005, 14, 102-114.	1.0	146
268	Changes in quality of life in patients with advanced cancer. <i>Journal of Psychosomatic Research</i> , 2005, 58, 497-504.	1.2	63
269	A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2005, 49, 401-412.	0.9	27
270	Nutritional Assessment in Cancer: Comparing the Mini-Nutritional Assessment (MNA) With the Scored Patient-Generated Subjective Global Assessment (PGSGA). <i>Nutrition and Cancer</i> , 2005, 53, 51-56.	0.9	113

#	ARTICLE	IF	CITATIONS
271	Factors Affecting Cytochrome P-450 3A Activity in Cancer Patients. <i>Clinical Cancer Research</i> , 2004, 10, 8341-8350.	3.2	119
272	Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. <i>British Journal of Clinical Pharmacology</i> , 2003, 57, 44-53.	1.1	63
273	Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. <i>Lancet Oncology</i> , The, 2003, 4, 224-232.	5.1	205
274	Baseline Nutritional Assessment in Advanced Cancer Patients Receiving Palliative Chemotherapy. <i>Nutrition and Cancer</i> , 2003, 46, 148-157.	0.9	77
275	The Erythromycin Breath Test For the Prediction of Drug Clearance. <i>Clinical Pharmacokinetics</i> , 2001, 40, 151-158.	1.6	61
276	Unusual Presentations of Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2001, 19, 909-911.	0.8	2
277	Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 45, 9-14.	1.1	14
278	Clinical and Preclinical Pharmacokinetics of Raltitrexed. <i>Clinical Pharmacokinetics</i> , 2000, 39, 429-443.	1.6	21
279	Vinblastine Pharmacokinetics in Patients with Non-Small Cell Lung Cancer Given Cisplatin. <i>Cancer Investigation</i> , 1999, 17, 479-485.	0.6	3
280	Clinical Pharmacokinetics of Docetaxel. <i>Clinical Pharmacokinetics</i> , 1999, 36, 99-114.	1.6	373
281	CLINICAL MANAGEMENT AND TREATMENT OUTCOMES OF MERKEL CELL CARCINOMA. <i>ANZ Journal of Surgery</i> , 1998, 68, 354-358.	0.3	51